resorcinol "ophtha" 1% øjendråber
actavis group ptc ehf. - resorcinol - øjendråber - 1%
stesolid 10 mg suppositorier
actavis group ptc ehf. - diazepam - suppositorier - 10 mg
stesolid 5 mg suppositorier
actavis group ptc ehf. - diazepam - suppositorier - 5 mg
sulfametizol "actavis" 500 mg tabletter
actavis group ptc ehf. - sulfamethizol - tabletter - 500 mg
ziprasidon "actavis" 20 mg kapsler, hårde
actavis group ptc ehf. - ziprasidonhydrochlorid - kapsler, hårde - 20 mg
ziprasidon "actavis" 40 mg kapsler, hårde
actavis group ptc ehf. - ziprasidonhydrochlorid - kapsler, hårde - 40 mg
ziprasidon "actavis" 60 mg kapsler, hårde
actavis group ptc ehf. - ziprasidonhydrochlorid - kapsler, hårde - 60 mg
ziprasidon "actavis" 80 mg kapsler, hårde
actavis group ptc ehf. - ziprasidonhydrochlorid - kapsler, hårde - 80 mg
desloratadine actavis
actavis group ptc ehf - desloratadin - rhinitis, allergic, perennial; urticaria; rhinitis, allergic, seasonal - antihistaminer til systemisk brug, - behandling af allergisk rhinitis og urticaria.
potactasol
actavis group ptc ehf - topotecan - uterine cervical neoplasms; small cell lung carcinoma - antineoplastiske midler - topotecan monotherapy is indicated for the treatment of:- patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy- patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate (see section 5. topotecan i kombination med cisplatin er indiceret til patienter med carcinoma af livmoderhalsen tilbagevendende efter strålebehandling, og for patienter med stadium iv sygdom. patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination (see section 5.